ADXN
HEALTHCAREAddex Therapeutics Ltd
$6.85-0.05 (-0.72%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving ADXN Today?
No stock-specific AI insight has been generated for ADXN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.41$12.05
$6.85
Fundamentals
Market Cap$8M
P/E Ratio—
EPS$-9.21
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume3K
Avg Volume (10D)—
Shares Outstanding1.2M
ADXN News
20 articles- Addex Reports Full Year 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Apr 30, 2026
- Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough ModelYahoo Finance·Apr 29, 2026
- Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026Yahoo Finance·Apr 23, 2026
- Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough ModelYahoo Finance·Apr 21, 2026
- Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder TreatmentYahoo Finance·Feb 3, 2026
- Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for SchizophreniaYahoo Finance·Jan 7, 2026
- Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co.Yahoo Finance·Dec 11, 2025
- Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst ...Yahoo Finance·Dec 4, 2025
- Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate UpdateYahoo Finance·Dec 4, 2025
- Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025Yahoo Finance·Dec 1, 2025
- Addex Increases Issued Share Capital to Create Treasury SharesYahoo Finance·Oct 29, 2025
- Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...Yahoo Finance·Oct 1, 2025
- Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate UpdateYahoo Finance·Sep 30, 2025
- Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025Yahoo Finance·Sep 26, 2025
- Addex Appoints Bank of New York Mellon as Depositary BankYahoo Finance·Sep 23, 2025
- European Market Insights: Addex Therapeutics Among 3 Promising Penny StocksYahoo Finance·Sep 15, 2025
- Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder ProgramsYahoo Finance·Jun 30, 2025
- Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric DisordersYahoo Finance·Jun 30, 2025
- Addex Shareholders Approve All Resolutions at Annual General MeetingYahoo Finance·Jun 25, 2025
- Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate UpdateYahoo Finance·Jun 19, 2025
All 20 articles loaded
Price Data
Open$0.00
Previous Close$6.90
Day High$0.00
Day Low$0.00
52 Week High$12.05
52 Week Low$5.41
52-Week Range
$5.41$12.05
$6.85
Fundamentals
Market Cap$8M
P/E Ratio—
EPS$-9.21
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume3K
Avg Volume (10D)—
Shares Outstanding1.2M
About Addex Therapeutics Ltd
Addex Therapeutics Ltd, a developing-stage biopharmaceutical company, discovers, develops and markets small molecule pharmaceuticals for central nervous system (CNS) disorders in Switzerland. The company is headquartered in Geneva, Switzerland.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—